Skip to main content
. 2019 Mar 29;3(4):537–550. doi: 10.1007/s41669-019-0131-6

Fig. 2.

Fig. 2

Base-case progression over time in a HbA1c, b SBP, and c BMI for the low-dose comparison, and in d HbA1c, e SBP, and f BMI for the high-dose comparison. Scenario progression over time in g HbA1c, h SBP, and i BMI for the low-dose comparison, and in j HbA1c, k SBP, and l BMI for the high-dose comparison. BMI body mass index, HbA1c glycated hemoglobin, SBP systolic blood pressure